Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Conditions
Brief summary
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Interventions
DEVICEClonoSEQ
Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
Sponsors
Stanford University
Adaptive Biotechnologies
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Immunophenotypically confirmed diagnosis of follicular lymphoma (FL), Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to CAR infusion * CAR-T product must meet manufacturer specifications * PET measurable disease at the time a decision is made to prescribe CAR treatment * Has sample from diagnosis or relapse available for genomic DNA extraction to identify patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion criteria
* Lack of archival diagnostic or fresh/archival relapse tissue for purposes of determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a clonotype identified by clonoSEQ, those patients will be removed from the study and excluded from analysis, but their samples will continued to be stored for future analysis as improvements to the analysis platform are made. * No patients are to be excluded on the basis of gender, race, ethnic background, sexual orientation, or other demographic characteristics.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome: Predicting Progression Free Survival | 0-18 months | Ability of ctDNA MRD assessment to predict progression-free survival (PFS) at 6 months following CAR infusion in DLBCL, FL and MCL patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Objective: Correlation of minimal residual disease and tumor burden | 0-18 months | -Determine the correlation between quantified MRD and metabolic tumor volume (MTV) |
| Secondary Objective continued: Looking at clinical information of minimal residual disease | 0-18 months | -Determine the clinical utility of MRD assessments in an exploratory analysis |
| Secondary Objective continued: Additional correlations | 0-18 months | -Determine the correlation between ctDNA-based and CTC-based MRD assessments in DLBCL/FL/MCL |
Countries
United States
Contacts
Primary ContactHeidi Simmons, PhD
Backup ContactMonica Gallucci
Outcome results
None listed